title: Treatment of subcutaneous phaeohyphomycosis and prospective follow-up of 17 kidney transplant recipients.
abstract: BACKGROUND
  Subcutaneous phaeohyphomycosis in solid organ recipients may have an adverse outcome.
  
  
  OBJECTIVE
  We sought to describe the disease course, treatment, and outcome of allograft function in kidney transplant recipients with phaeohyphomycosis.
  
  
  METHODS
  Seventeen patients were followed for a mean period of 25.4 months to analyze the clinical response to treatment.
  
  
  RESULTS
  There was no treatment failure or relapsing disease among 12 patients who completed treatment. Two patients were still in treatment with disease remission. One patient discontinued the study during treatment with partial remission, one died after finishing treatment with disease remission, and one was dropped from the study because contact was lost. Immunosuppressive regimens were not changed. Two of 17 patients had a significant reduction in allograft function.
  
  
  CONCLUSIONS
  The follow-up time was short and the number of patients was small.
  
  
  CONCLUSIONS
  The outcome of phaeohyphomycosis in kidney transplant recipients was favorable with minimal impact on renal allograft function.
authors.affiliation: Department of Dermatology, Federal University of São Paulo, São Paulo, Brazil.
authors.forename: Marília Marufuji
authors.initials: MM
authors.lastname: Ogawa
authors.forename: Nelson Zocoler
authors.initials: NZ
authors.lastname: Galante
authors.forename: Patrício
authors.initials: P
authors.lastname: Godoy
authors.forename: Olga
authors.initials: O
authors.lastname: Fischman-Gompertz
authors.forename: Flavia
authors.initials: F
authors.lastname: Martelli
authors.forename: Arnaldo Lopes
authors.initials: AL
authors.lastname: Colombo
authors.forename: Jane
authors.initials: J
authors.lastname: Tomimori
authors.forename: José Osmar
authors.initials: JO
authors.lastname: Medina-Pestana
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003404:Creatinine / Q000097:blood; D003881:Dermatomycoses / Q000175:diagnosis / Q000382:microbiology / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007668:Kidney / Q000503:physiopathology; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000175:diagnosis / Q000628:therapy
chemical_list: D000935:Antifungal Agents; D007166:Immunosuppressive Agents; D003404:Creatinine